Exercise and Rehabilitation for Individuals with Multiple Sclerosis
Overview
Authors
Affiliations
It is the coexistence of physical and cognitive impairments, together with emotional and social issues in a disease with an uncertain course, that makes MS rehabilitation unique and challenging. Inpatient rehabilitation improves functional independence but has only limited success improving the level of neurologic impairment. Benefits are usually not long lasting. Severely disabled people derive equal or more benefit than those who are less disabled, but cognitive problems and ataxia tend to be refractory. There is now good evidence that exercise can improve fitness and function for those with mild MS and helps to maintain function for those with moderate to severe disability. Therapy can be performed over 6 to 15 weeks in outpatient or home-based settings or as a weekly day program lasting several months. Several different forms of exercise have been investigated. For most individuals, aerobic exercise that incorporates a degree of balance training and socialization is recommended. Time constraints, access, impairment level, personal preferences, motivations, and funding sources influence the prescription for exercise and other components of rehabilitation. Just as immunomodulatory drugs must be taken on a continual basis and be adjusted as the disease progresses, so should rehabilitation be viewed as an ongoing process to maintain and restore maximum function and QOL.
Breaking boundaries: the transformative role of exercise in managing multiple sclerosis.
Saedmocheshi S, Yousfi N, Chamari K EXCLI J. 2024; 23:475-490.
PMID: 38741722 PMC: 11089092. DOI: 10.17179/excli2024-6932.
Ersoy T, Hocaoglu E PLoS One. 2023; 18(2):e0280505.
PMID: 36827290 PMC: 9955682. DOI: 10.1371/journal.pone.0280505.
Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.
Adibi I, Sanayei M, Tabibian F, Ramezani N, Pourmohammadi A, Azimzadeh K J Res Med Sci. 2022; 27:24.
PMID: 35419061 PMC: 8995308. DOI: 10.4103/jrms.jrms_1401_20.
Hubbard E, Motl R, Elmer D Trials. 2020; 21(1):972.
PMID: 33239079 PMC: 7687792. DOI: 10.1186/s13063-020-04887-x.
Huertas-Hoyas E, Maximo-Bocanegra N, Diaz-Toro C, Montes-Diez R, Perez-Corrales J, Sanchez-Herrera-Baeza P Occup Ther Int. 2020; 2020:6193938.
PMID: 32425718 PMC: 7211248. DOI: 10.1155/2020/6193938.